P.2.007 Lipolysaccharide-induced changes in brain stimulation reward: anhedonia or sickness behaviour?

Prins, Jolanda; Heesch, Floor van; Haan, Lydia de; Krajnc, A.M.; Kenny, Paul J.; Olivier, Berend; Kraneveld, Aletta D.; Korte, S. Mechiel

doi:10.1016/s0924-977x(11)70046-3

Search citation statements

Order By: Relevance

Paper Sections

Select...

Future Directions For Treatment Of Major Depressive Disorder1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2014

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipopolysaccharide (LPS), a component of the outer membrane of Gram‐negative bacteria that binds to toll‐like receptor 4 (TRL4) leading to the rapid systemic release of pro‐inflammatory cytokines, induces anhedonia in rats and mice as shown by increased thresholds in an intracranial self‐stimulation (ICSS) paradigm . LPS‐induced anhedonia was associated with increased extracellular levels of monoamine metabolites of serotonin and dopamine in the nucleus accumbens and prefrontal cortex, suggesting increased SERT and dopamine transporter (DAT) function .…”

Section: Future Directions For Treatment Of Major Depressive Disordermentioning

confidence: 99%

The Neuro‐Immune Axis: Prospect for Novel Treatments for Mental Disorders

Kraneveld

Theije

Heesch

et al. 2013

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Disturbed bidirectional pathways between the (central) nervous system and immune system have been implicated in various mental disorders, including depressive and neurodevelopmental disorders. In this minireview, the role of the neuroimmune axis and its targetability in relation to major depression and autism spectrum disorder will be discussed. All together, the management of these and possibly other multi-factorial mental disorders needs a new and integrated therapeutic approach. Pharmacologically bioactive molecules as well as medical nutrition targeting the (gut)-immune-brain axis could be such an approach.

show abstract

Section: Future Directions For Treatment Of Major Depressive Disordermentioning

confidence: 99%